In this review
Pay for the kind of support that solves the weekly problem
Arc-1 describes online intake review, possible practitioner contact by chat, call or video, and delivery after approval. Its support page also provides Chat with Doctor for prescription questions inside the relevant account order. That is practical access for treatment concerns; it is not scheduled dietitian visits or training sessions that you can put on a weekly calendar. [1] [2]
I would arrange those appointments separately when they are the main need. A difficult food routine or an activity plan that never happens needs more than a product page’s general support language. Choose this service for the assessment and continuing clinical contact it actually offers, then compare dedicated coaching according to the work someone will do with you.
A household budget needs the real tirzepatide bill
As with CoreAge Rx’s conflicting starting prices, Arc-1’s tirzepatide listings need clarification. The product page starts at $149 per month, while the catalogue starts at $199.99. Semaglutide’s own page starts at $199.99 monthly. The smaller tirzepatide figure should not win a comparison until the selected order explains its supply, initial payment and later charges. [3] [4] [5]
The product pages advertise a zero-dollar consultation and free shipping, but the whole commitment still needs a dated order summary. Get any recurring selection and cancellation deadline before deciding what fits the household calendar. The website is under construction; confirm the present pathway and state access before planning a transfer of ongoing care. [3] [4]
Added ingredients do not replace the practical plan
The tirzepatide page describes a compounded preparation containing glycine and B12 and suggests energy and tolerance benefits. Their inclusion does not establish less nausea, better muscle preservation or a predictable weight-loss result. A testimonial or result from another preparation cannot settle what this particular mixture will do. [3]
Compounded medicines are not FDA-approved. FDA’s current guidance also describes conditions that continue after the semaglutide and tirzepatide injection shortages were resolved. Keep the actual prescription and clinical reason with the prescriber and dispenser, and keep food access, suitable activity and symptom follow-up visible in the practical plan. [6] [7]
Check the return condition before treating the guarantee as flexibility
Arc-1 advertises a thirty-day satisfaction guarantee, but its support page says prescriptions are generally not returnable. The general policy requires unused goods in original condition, proof of purchase and approval before a return is sent. It is not a universal opportunity to use medication and then obtain a refund. [2] [3] [8]
The policy describes six to eight weeks for an approved refund to the original payment method and asks for damaged or incorrect deliveries to be reported immediately. Settle the actual return and renewal agreement before payment. For a reader whose main problem is sustaining meals or activity, compare scheduled support separately instead of assuming the medicine purchase supplies it. [8]
Understanding the cost
Current semaglutide page: from $199.99/month. Tirzepatide page: from $149/month; catalogue: from $199.99. Confirm the actual supplied prescription, first invoice, later charge and selected recurring terms before budgeting.
Build your cost estimateSources
- Arc-1: practitioner review and conditional fulfillment sequence
- Arc-1: clinician messaging, refills, lab results and prescription-return restriction
- Arc-1: compounded tirzepatide formulation and differing price statements
- Arc-1: current catalogue prices, construction notice and consultation invitation
- Arc-1: compounded semaglutide price, access and regulatory wording
- FDA: compounded drugs are not FDA-approved
- FDA: GLP-1 shortage resolution and current compounding conditions
- Arc-1: conditional returns, prior authorization and approved-refund timing
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.